REG - GSK PLC - CureVac/BioNTech mRNA patent litigation settlement

GSKAnnouncement

08/08/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250808:nRSH5771Ua&default-theme=true

RNS Number : 5771U  GSK PLC  08 August 2025

Issued: 8 August 2025, London UK

 

 

GSK Provides Update on US settlement of CureVac/BioNTech mRNA patent
litigation

 

·    CureVac will make an upfront settlement of $370 million to GSK

·    GSK will receive a 1% royalty on future Pfizer / BioNTech US sales of
influenza, COVID-19 and related combination mRNA vaccine products

 

 

GSK plc (LSE/NYSE: GSK) today announces that, in connection with the mRNA
patent settlement reached between CureVac and BioNTech on 7 August 2025, the
Company will receive an upfront settlement of $370 million. GSK will also
receive a 1% royalty in respect of US sales of influenza, COVID-19 and related
combination mRNA vaccine products by BioNTech and Pfizer from the beginning of
2025.

 

These payments are due to GSK in accordance with the terms of its existing
license agreement with CureVac. Of the upfront settlement amount, $320m will
be in cash. The remainder is attributed to the value of an amendment to GSK's
existing agreement with CureVac, which includes a significant reduction in
royalties to be paid by GSK on our potential future mRNA influenza, COVID-19
and influenza/COVID-19 combination products

 

If the pending acquisition of CureVac by BioNTech successfully closes, the
mRNA patent litigation between CureVac and BioNTech outside of the US will
also be settled. GSK would then be entitled to an additional $130 million in
cash and 1% royalty payments in respect of future sales outside of the
US by BioNTech and Pfizer. GSK would also benefit from reduced
milestones and a reduction in royalties payable in respect of GSK sales of
mRNA influenza, COVID-19 and influenza/COVID-19 combination products outside
of the US.

 

The upfront settlement amount will be recorded as other operating income in
GSK's financial results as an adjusting item in the income statement in the
third quarter of 2025. The 2025 and future royalty income will be recorded in
total and core results in the income statements.

 

This settlement does not impact GSK's enforcement of its own patents against
Pfizer and BioNTech in the U.S. and in Europe. GSK will continue with its
litigation against BioNTech and Pfizer for infringement of GSK's patents.

 

Simultaneously with the settlement, GSK has entered into a customary tender
and support agreement under which it has agreed to tender its approximately
16.6 million CureVac shares in the upcoming offer.

 

 

About GSK

GSK is a global biopharma company with a purpose to unite science, technology,
and talent to get ahead of disease together. Find out more at gsk.com.

 

 GSK enquiries
 Media:               Simon Moore        +44 (0) 20 8047 5502  (London)
                      Simon Steel        +44 (0) 20 8047 5502  (London)
                      Kathleen Quinn     +1 202 603 5003       (Washington DC)
                      Alison Hunt        +1 540 742 3391       (Washington DC)

 Investor Relations:  Constantin Fest    +44 (0) 7831 826525   (London)
                      James Dodwell      +44 (0) 20 8047 2406  (London)
                      Mick Readey        +44 (0) 7990 339653   (London)
                      Steph Mountifield  +44 (0) 7796 707505   (London)
                      Jeff McLaughlin    +1 215 751 7002       (Philadelphia)
                      Frannie DeFranco   +1 215 751 3126       (Philadelphia)

 

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made
by GSK, including those made in this announcement, are subject to risks and
uncertainties that may cause actual results to differ materially from those
projected. Such factors include, but are not limited to, those described in
the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2024, and
GSK's Q2 Results for 2025.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

79 New Oxford Street

London

WC1A 1DG

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCMZGGRKRVGKZG